Details
Stereochemistry | EPIMERIC |
Molecular Formula | C20H23N7O6.Ca |
Molecular Weight | 497.518 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Ca++].CN1C(CNC2=CC=C(C=C2)C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)CNC3=C1C(=O)N=C(N)N3
InChI
InChIKey=VWBBRFHSPXRJQD-ZEDZUCNESA-L
InChI=1S/C20H25N7O6.Ca/c1-27-12(9-23-16-15(27)18(31)26-20(21)25-16)8-22-11-4-2-10(3-5-11)17(30)24-13(19(32)33)6-7-14(28)29;/h2-5,12-13,22H,6-9H2,1H3,(H,24,30)(H,28,29)(H,32,33)(H4,21,23,25,26,31);/q;+2/p-2/t12?,13-;/m0./s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/26898294
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26898294
Methylenetetrahydrofolate reductase (MTHFR) is an enzyme required for the formation of 5-methyltetrahydrofolate (5-MTHF), a form of folate able to cross the blood-brain barrier and which is necessary as a substrate for the remethylation of homocysteine to methionine by methionine synthase. Patients with severe MTHFR deficiency cannot make 5-MTHF and have extremely low levels in the CSF. Only treatment with oral 5-MTHF given as calcium mefolinate resulted in an increase in CSF 5-MTHF.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Q99707 Gene ID: 4548.0 Gene Symbol: MTR Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/26898294 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
5-methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia. | 1998 Jan 27 |
|
Treatment with Mefolinate (5-Methyltetrahydrofolate), but Not Folic Acid or Folinic Acid, Leads to Measurable 5-Methyltetrahydrofolate in Cerebrospinal Fluid in Methylenetetrahydrofolate Reductase Deficiency. | 2016 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26898294
calcium mefolinate at doses of 15–60 mg/kg/day
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9462523
To study the actions of 5-methyltetrahydrofolate (5-MTHF) as an antioxidant, the effects of 5-MTHF (10, 100, and 1000 μmol/L) on superoxide generation by purified recombinant eNOS and xanthine oxidase/hypoxanthine were investigated. 5-MTHF dose-dependently reduced superoxide production by both xanthine oxidase and eNOS.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1379081
Created by
admin on Sat Dec 16 08:31:47 GMT 2023 , Edited by admin on Sat Dec 16 08:31:47 GMT 2023
|
PRIMARY | |||
|
173328
Created by
admin on Sat Dec 16 08:31:47 GMT 2023 , Edited by admin on Sat Dec 16 08:31:47 GMT 2023
|
PRIMARY | |||
|
101652053
Created by
admin on Sat Dec 16 08:31:47 GMT 2023 , Edited by admin on Sat Dec 16 08:31:47 GMT 2023
|
PRIMARY | |||
|
26560-38-3
Created by
admin on Sat Dec 16 08:31:47 GMT 2023 , Edited by admin on Sat Dec 16 08:31:47 GMT 2023
|
PRIMARY | |||
|
300000008647
Created by
admin on Sat Dec 16 08:31:47 GMT 2023 , Edited by admin on Sat Dec 16 08:31:47 GMT 2023
|
PRIMARY | |||
|
SUB33429
Created by
admin on Sat Dec 16 08:31:47 GMT 2023 , Edited by admin on Sat Dec 16 08:31:47 GMT 2023
|
PRIMARY | |||
|
9I291HQ60G
Created by
admin on Sat Dec 16 08:31:47 GMT 2023 , Edited by admin on Sat Dec 16 08:31:47 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD